← All trials
NCT00085163
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2004
- Primary completion
- Nov 1, 2005
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- Leiden UniversityStudy chair
- Federation Francophone de Cancerologie DigestiveCollaborator
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteCollaborator
- OncológicaCollaborator
- Gruppo Oncologico Chirurgico Cooperativo ItalianoCollaborator
- Dutch Colorectal Cancer GroupCollaborator
- Egyptian Foundation for Cancer ResearchCollaborator
- Gruppo Oncologico Italiano di Ricerca ClinicaCollaborator
- Institut Gustave RoussyStudy chair
- University of AmsterdamStudy chair
- Arbeitsgemeinschaft fur Internistische Onkologie (AIO)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.